IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
— ICVB-1042 is an oncolytic adenovirus for the treatment of advanced solid tumors —— Initial safety data expected in 2H 2023, followed by proof-of-concept data in 2024 — SAN DIEGO, CA., July 11, 2023 – IconOVir Bio, Inc. (IconOVir), a clinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the […]
IconOVir Bio to Present at Jefferies Healthcare Conference
SAN DIEGO, CA., May 31, 2023 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare […]
IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO, CA., March 7, 2023 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Oppenheimer 33rd […]
Julie Maltzman, M.D.
Dr. Julie Maltzman is a medical oncologist with broad experience built over 20 years across all phases of drug development. She joined IconOVir in Oct 2022 from a VP, Global Head of GI Cancers and Cancer Immunotherapy role at Roche/Genentech. There, Dr. Maltzman oversaw the successful registration and commercialization of Atezolizumab and Bevacizumab for HCC. […]
William Kaelin, M.D.
Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Kaelin was awarded the 2019 Nobel Prize for Physiology or Medicine, with co-recipients Sir Peter J. Ratcliffe and Dr. Gregg L. Semenza, for discoveries related to the […]
John Huynh, Ph.D.
John Huynh is the Chief Technology Officer at IconOVir Bio. He joins IconOVir from Ring Therapeutics, where he served as Senior Vice President of Technical Operations and was responsible for overseeing CMC development and manufacturing. Prior to joining Ring, he was a Vice President of Gene Therapy Technical Operations at PTC Therapeutics, where he helped […]
IconOVir Bio to Present at UBS Global Healthcare Conference
SAN DIEGO, CA., May 18, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Global […]
IconOVir Bio to Present at Jefferies Healthcare Conference
SAN DIEGO, CA., May 27, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare […]
IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042
Combined E1A and E4-ORF6/7 mutations demonstrate high degree of tumor selectivity in lead product candidate ICVB-1042 (formerly IOV-1042) IND filing for ICVB-1042 expected 1H 2022 Data published online in ASCO 2021 Annual Meeting Proceedings SAN DIEGO, CA., May 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic […]
IconOVir Bio Announces Formation of Scientific Advisory Board
Founding members bring deep expertise across interconnected fields of oncology research to provide strategic guidance and help advance programs into the clinic SAN DIEGO, CA., April 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced […]